Response to 'Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States"'

Pharmacoeconomics. 2019 Jul;37(7):965-967. doi: 10.1007/s40273-019-00803-7.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Cost-Benefit Analysis
  • Female
  • Humans
  • Indazoles
  • Indoles
  • Ovarian Neoplasms*
  • Phthalazines
  • Piperazines
  • Piperidines
  • United States

Substances

  • Indazoles
  • Indoles
  • Phthalazines
  • Piperazines
  • Piperidines
  • rucaparib
  • niraparib
  • olaparib